AMG 511

Research use only, not for human use.

AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks(Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively).

AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks(Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively). It exhibits anti-tumor activity in mouse glioblastoma xenograft model[1]. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease.

AMG 511 shows the inhibition of AKT (Ser473) phosphorylation in U87 malignant glioma (MG) cells with an IC50 of 4 nM.

AMG 511 potently blocks the targeted PI3K pathway in a mouse liver pharmacodynamic model (3-30 mg/kg; p.o.) and inhibits tumor growth in a U87 MG glioblastoma xenograft model (3-30 mg/kg; p.o.; daily; for 12 days).AMG 511 shows excellent in vivo efficacy and pharmacokinetic profile. Animal Model:Female CD1 NU/NU mice, with U87 MG glioblastoma xenograft model Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg Administration:Oral administration, daily, for 12 days Result:Inhibited tumor growth.Animal Model:Male Sprague-Dawley rats Dosage:1 mg/kg Administration:Oral administration (Pharmacokinetic Analysis)Result:Had a superior pharmacokinetic profile with low clearance (0.4 L/h/kg, 12% of liver blood flow), good oral bioavailability (F = 60%), and a commensurate high oral exposure (AUC = 5.0 μM·h).

——

PI3K/Akt/mTOR signaling

PI3K

PI3Kα|PI3Kβ|PI3Kγ|PI3Kδ

——

——

1253573-53-3

517.58

C22H28FN9O3S

>98% (HPLC)

DMSO:33.33 mg/mL (64.40 mM; Need ultrasonic)

C[C@H](c(cc1-c2nc(N)nc(C)n2)cnc1Nc(cc1F)cnc1OC)N(CC1)CCN1S(C)(=O)=O

——

(-20℃)

With Ice Pack

≥ 2 years